The purpose of this study is to determine if Oxymorphone Extended Release is effective and
safe in treating chronic pain in patients with cancer or neuropathic pain.
Drug: Oxymorphone Extended Release
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT00911261
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
≥ 18 years of age or older, with moderate to severe chronic malignant and/or neuropathic pain of at least 3 months duration and either:
have an initial pain intensity score of greater than 4 on a 10-point scale using BPI Question 5, if sub-optimally responding to their current analgesic regimen, or
have intolerable side effects to one or more components of their current opioid-containing analgesic regimen.
Currently receive a stable (at least 2 weeks duration) analgesic regimen
If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method).
Understand written and spoken English
Have been informed of the nature of the study and provided written informed consent Additional Inclusion Criteria for Cancer Patients Only:
Have a life expectancy of at least 12 months Additional Inclusion Criteria for Neuropathic Patients Only:
Have a diagnosis of:
post-herpetic neuralgia (PHN)
diabetic neuropathy (DN)
complex regional pain syndrome (CRPS)
idiopathic sensory neuropathy
traumatic peripheral neuropathy
central neuropathic pain condition (spinal cord injury, post-stroke pain), OR
other peripheral neuropathy (upon mutual agreement of the sponsor and investigator).
Have a positive pregnancy test (females only)
Have a history of or active asthma or emphysema
Have clinically significant hepatic impairment
Have a history of alcohol or substance abuse within the last 3 years
Have a history of opioid abuse within 6 months prior to study entry
Have a known allergy or significant reaction to opioids, including codeine
Have a known oxymorphone sensitivity or allergy
Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication
All locations for NCT00911261
View full eligibility
Tris trial is registered with FDA with number: NCT00911261. The sponsor of the trial is Endo Pharmaceuticals and it is looking for 223 volunteers for the current phase.
Official trial title: An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.